ArticleFrontiers in genome editing2025
CRISPR-FMC: a dual-branch hybrid network for predicting CRISPR-Cas9 on-target activity.
Article in Frontiers in genome editing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurately predicting the on-target activity of sgRNAs remains a challenge in CRISPR-Cas9 applications, due to the limited generalization of existing models across datasets, small-sample settings, and complex sequence contexts. Current methods often rely on shallow architectures or unimodal encodings, limiting their ability to capture the intricate dependencies underlying Cas9-mediated cleavage. Methods: We present CRISPR-FMC, a dual-branch hybrid neural network that integrates One-hot encoding with contextual embeddings from a pre-trained RNA-FM model. Multi-scale convolution (MSC), BiGRU, and Transformer blocks are employed to extract hierarchical sequence features, while a bidirectional cross-attention mechanism with a residual feedforward network enhances multimodal fusion and generalization. Results: Across nine public CRISPR-Cas9 datasets, CRISPR-FMC consistently outperforms existing baselines in both Spearman and Pearson correlation metrics, showing particularly strong performance under low-resource and cross-dataset conditions. Ablation experiments confirm the contribution of each module, and base substitution analysis reveals a pronounced sensitivity to the PAM-proximal region. Discussion: The PAM-proximal sensitivity aligns with established biological evidence, indicating the model's capacity to capture biologically relevant sequence determinants. These results demonstrate that CRISPR-FMC offers a robust and interpretable framework for sgRNA activity prediction across heterogeneous genomic contexts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.